MARKET

PCSA

PCSA

Processa Pharmaceuticals Inc
NASDAQ
2.430
-0.070
-2.80%
After Hours: 2.422 -0.009 -0.35% 18:08 08/14 EDT
OPEN
2.490
PREV CLOSE
2.500
HIGH
2.525
LOW
2.370
VOLUME
50.19K
TURNOVER
--
52 WEEK HIGH
14.24
52 WEEK LOW
1.670
MARKET CAP
6.73M
P/E (TTM)
-0.2229
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PCSA last week (0803-0807)?
Weekly Report · 5d ago
Processa Pharmaceuticals Shareholders Approve Key Governance Changes
TipRanks · 08/04 21:45
Weekly Report: what happened at PCSA last week (0727-0731)?
Weekly Report · 08/03 09:44
Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals
NASDAQ · 07/31 14:51
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/29 17:06
Crude Oil Surges 7%; General Dynamics Posts Upbeat Earnings
Benzinga · 07/29 16:02
Dow Tumbles 400 Points; Procter & Gamble Shares Fall After Q4 Results
Benzinga · 07/29 13:46
Processa Pharmaceuticals To Acquire Vidya Therapeutics, Launch $200M Financing; Stock Down
NASDAQ · 07/29 13:44
More
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.

Webull offers Processa Pharmaceuticals Inc stock information, including NASDAQ: PCSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCSA stock methods without spending real money on the virtual paper trading platform.